GlaxoSmithKline has struck a three-way agreement worth $16bn with Novartis to reorganise their businesses. Lex's Joseph Cotterill and Robert Armstrong discuss whether the reorganisation aids a prime objective of drugmakers: selling more drugs.<br /><br />For more video content from the Financial Times, visit http://www.FT.com/video<br /><br />Subscribe to the Financial Times on YouTube; http://goo.gl/vUQx5k<br />Twitter https://twitter.com/ftvideo<br />Facebook https://www.facebook.com/financialtimes
